Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice

Neoplasma

Volumn 58, Issue 6, 2011, Pages 538-547

  Dai, L ^a   Cheng, L ^a   Zhang, X ^a   Jiang, Q ^a,b   Zhang, S ^a   Wang, S ^a   Li, Y ^a   Chen, X ^a   Du, T ^a   Yang, Y ^a   Tian, H ^a   Fan, P ^a   Yan, N ^a   Wei, Y ^a   Deng, H ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Breast cancer; Metastasis; RNA interference; STAT3

Indexed keywords

CD31 ANTIGEN; CYCLINE; PLASMID VECTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA FLANKING REGION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; GROWTH INHIBITION; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL ADHESION; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG ANTAGONISM; GENE VECTOR; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; UMBILICAL VEINS; WOUND HEALING;

EID: 84863183409     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_06_538     Document Type: Article

References (44)

1. STEEG PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12: 895-904.
2. FIDLER IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458. doi:10.1038/nrc1098.
3. KAMANGAR F, DORES GM and ANDERSON WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150. doi:10.1200/JCO.2005.05.2308.
4. GARCIA R, YU CL, HUDNALL A, CATLETT R, NELSON KL et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997; 8: 1267-1276.
5. XIE TX, HUANG FJ, ALDAPE KD, KANG SH, LIU M et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006; 66: 3188-3196. doi:10.1158/0008-5472.CAN-05-2674.
6. Stetler-Stevenson WG, Hewitt R and Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 147-154. doi:10.1006/scbi.1996.0020.
7. CHENG GZ, ZHANG WZ, SUN M, WANG Q, COPPOLA D et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 2008; 283: 14665-14673. doi:10.1074/jbc.M707429200.
8. YANG J, MANI SA, DONAHER JL, RAMASWAMY S, ITZYKSON RA et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939. doi:10.1016/j.cell.2004.06.006.
9. DEO DD, AXELRAD TW, ROBERT EG, MARCHESILI V, BAZAN NG et al. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J Biol Chem 2002; 277: 21237-21245. doi:10.1074/jbc.M110955200.
10. SCHAEFER LK, REN Z, Fuller GN and Schaefer TS. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 2002; 21: 2058-2065. doi:10.1038/sj.onc.1205263.
11. HANNON GJ. RNA interference. Nature 2002; 418: 244-251. doi:10.1038/418244a.
12. PAI SI, LIN YY, MACAES B, MENESHIAN A, HUNG CF et al. Prospects of RNA interference Therapy for cancer. Gene Ther 2006; 13: 464-477. doi:10.1038/sj.gt.3302694.
13. HANNON GJ AND ROSSI JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378. doi:10.1038/nature02870.
14. PULASKI BA, TERMAN DS, KHAN S, MULLER E and Ostrand-Rosenberg S. Cooperativity of staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000; 60: 2710-2715.
15. CRONIN PA, WANG JH and REDMOND HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer 2010; 10: 225. doi:10.1186/1471-2407-10-225.
16. WALSH C, TANJONI I, URYU S, TOMAR A, NAM JO et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 2010; 9: 778-790. doi:10.4161/cbt.9.10.11433.
17. KORTYLEWSKI M, SWIDERSKI P, HERRMANN A, WANG L, KOWOLIK C et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR7 agonist enhances antitumor immune responses. Nat Biotechnol 2009; 27: 925-932. doi:10.1038/nbt.1564.
18. WYCKOFF JB, JONES JG, CONDEELIS JS AND SEGALL JE. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 2000; 60: 2504-2511.
19. CHAMBERS AF, GROOM AC and MACDONALD IC. Dissemination and growth of cancer cells in metastatic sites. Nature Rev Cancer 2002; 2: 563-572. doi:10.1038/nrc865.
20. EUBANK TD, ROBERTS RD, KHAN M, CURRY JM, NUOVO GJ et al. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res 2009; 69: 2133-2140. doi:10.1158/0008-5472.CAN-08-1405.
21. BURSTEIN HJ, CHEN YH, PARKER LM, SAVOIE J, YOUNGER J et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine. Clin Cancer Res 2008; 14: 7871-7877. doi:10.1158/1078-0432.CCR-08-0593.
22. NADIMINTY N, LOU W, LEE SO, LIN X, TRUMP DL et al.Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci USA 2006; 103: 7264-7269. doi:10.1073/pnas.0509808103.
23. NIU G., WRIGHT KL, MA Y, WRIGHT GM, HUANG M et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005; 25: 7432-7440. doi:10.1128/MCB.25.17.7432-7440.2005.
24. DECHOW TN, PEDRANZINI L, LEITCH A, LESLIE K, GERALD WL et al. Requirement of matrix metalloproteinase9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 2004; 101: 10602-10607. doi:10.1073/pnas.0404100101.
25. VERNON AE and Labonne C. Tumor metastasis: A new Twist on epithelial mesenchymal transitions. Curr Biol 2004; 14: R719-R721. doi:10.1016/j.cub.2004.08.048.
26. MA L, REINHARDT F, PAN E, SOUTSCHED J, BHAT B et al. Therapeutic silencing of mir-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnol 2010; 28: 341-347. doi:10.1038/nbt.1618.
27. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115. doi:10.1016/S1074-7613(00)80011-4.
28. NIU, G, HELLER R, Catlett-Falcone R, COPPOLA D, JAROSZESKI M et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999; 59: 5059-5063.
29. BOWMAN T, BROOME MA, SINIBALDI D, WHARTON W, PLEDGER WJ et al. Stat3-mediated Myc expression is required for Src transfor-mation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001; 98: 7319-7324. doi:10.1073/pnas.131568898.
30. BROMBERG JF, WRZESZCZYNSKA MH, DEVGAN G, ZHAO Y, PESTELL RG et al. Stat3 as an oncogene. Cell 1999; 98: 295-303. doi:10.1016/S0092-8674(00)81959-5.
31. FOLKMAN J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16): 15-18. doi:10.1016/S0093-7754(02)70065-1.
32. HUANG F, TONG XY, FU LQ AND ZHANG RH. Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin 2008; 519-525. doi:10.1111/j.1745-7270.2008.00424.x.
33. GRITSKO T, WILLIAMS, TURKSON J, KANEKO S, BOWMAN T et al. Persistent activation of stat3 signaling induces surviving gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12:11-19. doi:10.1158/1078-0432.CCR-04-1752
34. GUO Y, GUO H, ZHANG L, XIE H, ZHAO X et al. Genomic analysis of anti-hepatitis B virus activity by small interfering RNA and lamivudine in stable HBV-producing cells. Journal of Virology 2005; 79: 14392-14403. doi:10.1128/JVI.79.22.14392-14403.2005.
35. ZHDANOV RI, PODOBED OV and VLASSOV VV. Cationic liposome-DNA complexes-lipoplexes-forgene transfer and therapy. Bioelectrochemistry 2002; 58: 53-64. doi:10.1016/S1567-5394(02)00132-9.
36. YOUNG LS and MAUTNER V. The promise and potential hazards of adenovirus gene therapy. Gut 2001; 48 733-736. doi:10.1136/gut.48.5.733.
37. JIAO X, WANG RY, QIU Q, ALTER HJ and SHIH JW. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol 2004; 85(Pt 6): 1545-1553. doi:10.1099/vir.0.79896-0.
38. ZELPHATI O and Szoka FC Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996; 93: 11493-11498. doi:10.1073/pnas.93.21.11493.
39. SANGARE L, MORISSET R, OMRI A and RAVAOARINORO M. Incorporation rates, stabilities, cytotoxicities and release of liposomal tetracycline and doxycycline in human serum. J Antimicrob Chemother 1998; 42: 831-834. doi:10.1093/jac/42.6.831.
40. YANG Y, BAI Y, XIE G, ZHANG N, MA YP et al. Efficient inhibition of non-small cell lung Cancer xenograft by systemic delivery of plasmid encoding short hairpin RNA targeting VEGF. Cancer Biotherapy & Radiopharmaceuticals 2010; 25: 65-73. doi:10.1089/cbr.2009.0692.
41. WAN Y, HUANG AL, YANG Y, XIE G, CHEN X et al. A vector-based short hairpin RNA targeting Aurora A inhibits breast cancer growth. International Journal of Oncology 2010; 36: 1121-1128.
42. DUCHAINE TF and SLACK FJ. RNA interference and micro-RNA-oriented therapy in cancer: rationales, promises, and challenges. Curr Oncol 2009; 16: 61-66. doi:10.3747/co.v16i4.486.
43. RAO DD, VORHIES JS, SENZER N and NEMUNAITIS J. siRNA vs. shRNA: Similarities and differences. Adv Drug Deliv Rev 2009; 61:746-759. doi:10.1016/j.addr.2009.04.004.
44. PAGET S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133: 571-573. doi:10.1016/S0140-6736(00)49915-0.